RZLT

+ Watchlist + Portfolio

Rezolute, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.07
52-Week Range: $1.07 – $11.46
Market Cap: $387.86M
P/E (TTM): —
EPS (TTM): -0.75
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.59
PEG Ratio: —
Return on Equity: -59.04%
Return on Assets: -35.32%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 9.68
Debt/Equity: 0.01
Total Debt: $934.00K
Free Cash Flow: $-36.37M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $280.99M

RZLT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$32.49M	$43.81M	$55.74M	$61.53M
Selling, General & Admin	$9.36M	$12.18M	$14.68M	$18.37M
Operating Expenses	$41.61M	$55.99M	$70.42M	$79.89M
Operating Income	-$41.61M	-$55.99M	-$70.42M	-$79.89M
EBITDA	-$39.24M	-$55.96M	-$70.39M	-$79.86M
Pretax Income	-$41.06M	-$51.79M	-$68.46M	-$74.41M
Net Income	-$41.06M	-$51.79M	-$68.46M	-$74.41M
Diluted EPS	-2.32	-1.01	-1.33	-0.98
Diluted Shares	19.49M	51.19M	51.47M	76.00M

RZLT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$150.41M	$16.04M	$70.40M	$94.11M
Current Assets	$152.10M	$104.91M	$128.65M	$171.15M
Total Assets	$152.42M	$123.72M	$132.74M	$175.49M
Current Liabilities	$2.46M	$5.20M	$9.61M	$11.91M
Total Debt	$188.00K	$2.48M	$2.23M	$1.61M
Total Liabilities	$2.95M	$7.55M	$11.73M	$13.36M
Retained Earnings	-$209.20M	-$260.99M	-$329.44M	-$403.86M
Shareholders' Equity	$149.47M	$116.17M	$121.00M	$162.13M
Working Capital	$149.64M	$99.71M	$119.05M	$159.23M

RZLT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$39.62M	-$44.48M	-$57.37M	-$69.08M
Capital Expenditure	—	-$153.00K	—	—
Free Cash Flow	-$39.62M	-$44.63M	-$57.37M	-$69.08M
Depreciation & Amortisation	$13.00K	$30.00K	$36.00K	$31.00K
Stock-Based Compensation	$3.69M	$7.27M	$7.36M	$7.12M
Investing Cash Flow	$0.00	-$101.46M	$48.70M	-$14.54M
Financing Cash Flow	$148.98M	$11.57M	$63.03M	$107.33M
Net Change in Cash	$109.36M	-$134.37M	$54.36M	$23.71M

RZLT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$15.28M	$20.86M	$13.15M	$14.35M	$11.41M
Selling, General & Admin	$4.74M	$4.99M	$6.67M	$9.87M	$5.95M
Operating Expenses	$20.02M	$25.85M	$19.82M	$24.22M	$17.37M
Operating Income	-$20.02M	-$25.85M	-$19.82M	-$24.22M	-$17.37M
EBITDA	-$20.02M	-$25.84M	-$19.81M	-$24.21M	-$17.36M
Pretax Income	-$18.91M	-$24.39M	-$18.15M	-$22.77M	-$16.17M
Net Income	-$18.91M	-$24.39M	-$18.15M	-$22.77M	-$16.17M
Diluted EPS	-0.27	-0.26	-0.18	-0.22	-0.16
Diluted Shares	70.03M	94.34M	103.42M	103.69M	104.04M

RZLT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$14.60M	$94.11M	$9.10M	$11.94M	$11.24M
Current Assets	$88.73M	$171.15M	$154.71M	$135.11M	$122.05M
Total Assets	$94.74M	$175.49M	$158.66M	$138.63M	$125.46M
Current Liabilities	$10.53M	$11.91M	$10.21M	$9.53M	$7.70M
Total Debt	$1.77M	$1.61M	$1.45M	$1.28M	$1.11M
Total Liabilities	$12.17M	$13.36M	$11.50M	$10.63M	$8.63M
Retained Earnings	-$379.47M	-$403.86M	-$422.01M	-$444.78M	-$460.95M
Shareholders' Equity	$82.57M	$162.13M	$147.17M	$128.00M	$116.83M
Working Capital	$78.21M	$159.23M	$144.50M	$125.58M	$114.34M

RZLT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$17.40M	-$22.00M	-$17.43M	-$20.32M	-$13.73M
Free Cash Flow	-$17.40M	-$22.00M	-$17.43M	-$20.32M	-$13.73M
Depreciation & Amortisation	$7.00K	$8.00K	$8.00K	$7.00K	$8.00K
Stock-Based Compensation	$1.91M	$2.37M	$2.53M	$3.41M	$4.42M
Investing Cash Flow	$23.05M	$346.00K	-$68.49M	$22.81M	$12.28M
Financing Cash Flow	$10.00K	$101.16M	$911.00K	$356.00K	$747.00K
Net Change in Cash	$5.66M	$79.51M	-$85.01M	$2.85M	-$708.00K

Market Snapshot

About

Rezolute, Inc. is a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases. The company focuses on treatments for congenital hyperinsulinism, severe hypoglycemia, and diabetes using novel formulations and delivery mechanisms. Rezolute leverages proprietary technology platforms to address unmet needs in rare and orphan endocrine disorders.